You just read:

Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

News provided by

Amgen

Nov 30, 2018, 16:00 ET